Global Blood Therapeutics, Inc. (NASDAQ:GBT) – Equities research analysts at SunTrust Banks raised their FY2018 earnings per share (EPS) estimates for Global Blood Therapeutics in a research note issued to investors on Monday. SunTrust Banks analyst Y. Suneja now expects that the company will post earnings of ($3.30) per share for the year, up from their previous forecast of ($4.10). SunTrust Banks currently has a “Buy” rating and a $67.00 price target on the stock. SunTrust Banks also issued estimates for Global Blood Therapeutics’ FY2019 earnings at ($3.45) EPS, FY2020 earnings at ($3.55) EPS and FY2021 earnings at ($4.40) EPS.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the previous year, the firm earned ($0.58) EPS.

Several other equities analysts have also recently issued reports on GBT. BidaskClub cut shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Wedbush reiterated an “outperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a research note on Monday. ValuEngine downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Cowen reiterated an “outperform” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research note on Monday, August 14th. Finally, HC Wainwright began coverage on shares of Global Blood Therapeutics in a research note on Friday, December 1st. They issued a “buy” rating and a $73.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating to the stock. Global Blood Therapeutics has an average rating of “Buy” and a consensus price target of $56.38.

Global Blood Therapeutics (GBT) traded up $3.55 during mid-day trading on Wednesday, hitting $43.85. 1,371,600 shares of the company were exchanged, compared to its average volume of 988,892. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $44.30.

In other news, Director Charles J. Homcy sold 70,000 shares of the company’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares of the company’s stock, valued at approximately $2,830,652.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $32.65, for a total value of $97,950.00. Following the completion of the sale, the insider now directly owns 138,455 shares of the company’s stock, valued at $4,520,555.75. The disclosure for this sale can be found here. Insiders have sold a total of 88,500 shares of company stock valued at $3,003,350 over the last three months. Company insiders own 5.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA boosted its position in Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after acquiring an additional 3,975 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Global Blood Therapeutics by 10.1% during the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after buying an additional 440 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Global Blood Therapeutics during the third quarter valued at approximately $200,000. Trexquant Investment LP purchased a new position in Global Blood Therapeutics in the third quarter worth $202,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Global Blood Therapeutics in the third quarter worth $205,000. 90.48% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Global Blood Therapeutics, Inc. to Post FY2018 Earnings of ($3.30) Per Share, SunTrust Banks Forecasts (GBT)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/08/global-blood-therapeutics-inc-to-post-fy2018-earnings-of-3-30-per-share-suntrust-banks-forecasts-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.